What do Amgen, Biogen, and Takeda have in common?
Leaders of research and development at the three biopharma companies shared a stage Thursday at the STAT 2024 Summit in Boston and offered their insights on their differing challenges in a hot space for obesity drugs, an industry that doesn’t favor midsize companies, and a disappointing market for Alzheimer’s treatments — so far.
Their common strategy, in Amgen Chief Scientific Officer Jay Bradner’s words, is to “make medicines for some of the toughest targets for the toughest diseases.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in